Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 5:05 pm Sale | 13G | Cullinan Therapeutics Inc. CGEM | Blue Owl Capital Holdings LP | 2,010,972 3.450% | -1,408,870 (-41.20%) | View |
| 2024-11-14 4:24 pm Purchase | 13G | Cullinan Therapeutics Inc. CGEM | BIOTECHNOLOGY VALUE FUND L P | 5,796,433 9.990% | 1,403,112 (+31.94%) | View |
| 2024-11-12 2:23 pm Unchanged | 13G | Cullinan Therapeutics Inc. CGEM | VANGUARD GROUP INC | 2,998,714 5.170% | 0 (Unchanged) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | Cullinan Therapeutics Inc. CGEM | BlackRock Inc. BLK | 4,338,725 7.500% | 0 (Unchanged) | View |
| 2024-11-04 11:18 am Purchase | 13G | Cullinan Therapeutics Inc. CGEM | VANGUARD GROUP INC | 2,998,714 5.170% | 1,227,271 (+69.28%) | View |
| 2024-10-22 3:24 pm Purchase | 13G | Cullinan Therapeutics Inc. CGEM | BlackRock Inc. BLK | 4,338,725 7.500% | 4,338,725 (New Position) | View |
| 2024-06-07 1:30 pm Purchase | 13G | Cullinan Therapeutics Inc. CGEM | BlackRock Inc. BLK | 2,748,730 4.800% | 286,456 (+11.63%) | View |
| 2024-04-24 5:50 pm Purchase | 13G | Cullinan Therapeutics Inc. CGEM | Flynn James E | 3,283,824 5.710% | 3,283,824 (New Position) | View |
| 2024-02-14 9:01 pm Purchase | 13G | Cullinan Therapeutics Inc. CGEM | Blue Owl Capital Holdings LP | 3,419,842 7.990% | 3,419,842 (New Position) | View |
| 2024-02-14 4:59 pm Sale | 13G | Cullinan Therapeutics Inc. CGEM | Jovan-Embiricos Morana | 2,177,461 5.090% | -1,606,510 (-42.46%) | View |
| 2024-02-14 10:16 am Sale | 13G | Cullinan Therapeutics Inc. CGEM | BIOTECHNOLOGY VALUE FUND L P | 4,393,321 9.990% | -3,115,738 (-41.49%) | View |
| 2024-02-13 5:02 pm Sale | 13G | Cullinan Therapeutics Inc. CGEM | VANGUARD GROUP INC | 1,771,443 4.140% | -1,041,522 (-37.03%) | View |
| 2024-02-06 10:09 am Purchase | 13G | Cullinan Therapeutics Inc. CGEM | FRANKLIN RESOURCES INC BEN | 3,281,280 7.700% | 3,281,280 (New Position) | View |
| 2024-01-29 5:25 pm Purchase | 13G | Cullinan Therapeutics Inc. CGEM | BlackRock Inc. BLK | 2,462,274 5.800% | 425,623 (+20.90%) | View |
| 2023-09-07 09:38 am Sale | 13G | Cullinan Therapeutics Inc. CGEM | BlackRock Inc. BLK | 2,036,651 4.800% | -469,564 (-18.74%) | View |
| 2023-02-15 11:42 am Sale | 13G | Cullinan Therapeutics Inc. CGEM | Jovan-Embiricos Morana | 3,783,971 8.300% | -2,495,742 (-39.74%) | View |
| 2023-02-14 11:53 am Purchase | 13G | Cullinan Therapeutics Inc. CGEM | BIOTECHNOLOGY VALUE FUND L P | 7,509,059 16.400% | 2,139,600 (+39.85%) | View |
| 2023-02-13 12:36 pm Purchase | 13G | Cullinan Therapeutics Inc. CGEM | CHI Advisors LLC | 3,317,544 7.250% | 840,824 (+33.95%) | View |
| 2023-02-09 11:16 am Purchase | 13G | Cullinan Therapeutics Inc. CGEM | VANGUARD GROUP INC | 2,812,965 6.150% | 446,157 (+18.85%) | View |
| 2023-02-03 12:10 pm Purchase | 13G | Cullinan Therapeutics Inc. CGEM | BlackRock Inc. BLK | 2,506,215 5.500% | 2,506,215 (New Position) | View |